Literature DB >> 17301572

Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).

Martin Tolstrup1, Joanna Selzer-Plön, Alex L Laursen, Lone Bertelsen, Jan Gerstoft, Mogens Duch, Finn S Pedersen, Lars Ostergaard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17301572     DOI： 10.1097/QAD.0b013e3280187558

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  14 in total

1.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

2.  Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function.

Authors:  Dirk Eggink; Ilja Bontjer; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 3.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

4.  HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Authors:  Dirk Eggink; Steven W de Taeye; Ilja Bontjer; Per Johan Klasse; Johannes P M Langedijk; Ben Berkhout; Rogier W Sanders
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

5.  Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.

Authors:  Kazuya Shimura; Daisuke Nameki; Keiko Kajiwara; Kentaro Watanabe; Yasuko Sakagami; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Stefan G Sarafianos; Eiichi N Kodama
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

6.  Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.

Authors:  Kazuki Izumi; Kumi Kawaji; Fusasko Miyamoto; Kazuki Shimane; Kazuya Shimura; Yasuko Sakagami; Toshio Hattori; Kentaro Watanabe; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka; Mitsuo Kaku; Stefan G Sarafianos; Eiichi N Kodama
Journal:  Int J Biochem Cell Biol       Date:  2013-01-26       Impact factor: 5.085

7.  Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Authors:  Tea Kirkegaard; Adam Wheatley; Jesper Melchjorsen; Shervin Bahrami; Finn S Pedersen; Robert J Center; Damian F J Purcell; Lars Ostergaard; Mogens Duch; Martin Tolstrup
Journal:  Virol J       Date:  2011-08-01       Impact factor: 4.099

8.  The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.

Authors:  Francesc Cunyat; Silvia Marfil; Elisabet García; Valentina Svicher; Nuria Pérez-Alvárez; Marta Curriu; Carlo Federico Perno; Bonaventura Clotet; Julià Blanco; Cecilia Cabrera
Journal:  Retrovirology       Date:  2012-02-14       Impact factor: 4.602

Review 9.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

Review 10.  HIV-1 drug-resistance and drug-dependence.

Authors:  Chris Baldwin; Ben Berkhout
Journal:  Retrovirology       Date:  2007-10-25       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.